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ublic concern about ethics in 
HIV-prevention trials intensiﬁ  ed 
in the last 18 months, reaching a 
ﬂ  ashpoint that resulted in the halting 
of two clinical trials to test the efﬁ  cacy 
of tenofovir as a possible method of 
pre-exposure prophylaxis (PREP) 
against HIV infection. A reverse 
transcriptase inhibitor, tenofovir is 
viewed as a promising candidate for 
PREP because it is already being widely 
used as a component in combination-
therapy regimens to suppress viral 
replication, it has a once-daily dosing 
schedule, and clinical trials have shown 
a low level of side effects [1].
    Six randomized, placebo-controlled 
trials to test tenofovir among high-
risk populations have been planned 
to date. Two of these were halted by 
government order of the host country: 
one in Cambodia in August 2004 and 
one in Cameroon in February 2005. In 
March 2005, the PREP Nigerian trial 
was also stopped; but this occurred 
because, according to the trial sponsor, 
the local clinical trial site was unable 
to achieve “the necessary scientiﬁ  c 
standards.”
    Intense controversy among trial 
sponsors, HIV/AIDS activists, and 
some trial participants gave rise to 
these politicized, trial-halting decisions. 
Voices on all sides have expressed 
strong opinions – with some charging 
that the rights and interests of the 
highly vulnerable populations enrolling 
in the trials were not adequately 
protected and that the trials were, 
therefore, unethical. 
    One key issue in this debate has been 
the provision of antiretroviral treatment 
(ART) to those who seroconvert during 
the trial—generally referred to as 
“access to care.” Public perception of 
researchers’ responsibility in this area 
is rooted in the physician’s traditional 
obligation to provide research 
participants with the best possible care. 
What this tradition does not address, 
however, is the challenge of meeting 
such an obligation in an environment 
of massive inequalities.
    The Joint United Nations Programme 
on HIV/AIDS (UNAIDS) has held 
several regional and international 
deliberations in the last seven years that 
addressed (among other issues) the 
question of access to care. In July 2003, 
they convened “HIV Treatment for 
Intercurrent Infections,” a consultation 
in which vaccine and microbicide 
researchers came together with 
social scientists, ethicists, community 
representatives, and donors. Together 
they afﬁ  rmed that providing ART 
conforms to several fundamental 
ethical principles:   beneﬁ  cence  , by which 
researchers are obliged to maximize 
beneﬁ  ts to participants;   reciprocity  , which 
suggests that those who contribute 
important data to the study by 
becoming infected deserve something 
in return; and   justice  , which requires 
that all seroconverting trial participants 
be treated equally, regardless of 
location [2].
    Some bioethicists argue that 
the provision of ART to those who 
seroconvert during an HIV-prevention 
trial is ethically obligatory. Others 
contend that it does not qualify as a 
mandatory obligation but that it is, 
nevertheless, “morally praiseworthy”—
something that   should   be done if at 
all possible. Despite these differing 
deﬁ  nitions, existing social and political 
realities have now rendered provision 
of access to care a critical factor in a 
trial’s ability to go forward. 
    Why the Global Campaign 
for Microbicides Is Involved
    The Global Campaign for Microbicides 
is a broad-based international coalition 
working to accelerate access to new 
HIV-prevention options. We mobilize 
the civil society arm of the microbicide 
movement by serving as a unifying 
umbrella under which activists, non-
governmental organizations and other 
civil society voices work collectively to 
advance this common goal. 
    Since its inception in 1998, the 
Global Campaign has helped lead 
the search for practical solutions 
to the ethical quandaries inherent 
in microbicide trial design and 
implementation. Faced with the 
possibility that microbicide trials could 
be shut down if the issue of access to 
care was not adequately addressed, 
we saw the need to articulate a clear 
position. We developed this position to 
address the ethical tensions that have 
surfaced in a way that both responds to 
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community concerns and contributes 
to resolving the impasses that have 
resulted in trial closures. 
    Chief among these is the question 
of   how   a sponsor can effectively assure 
access to care in the developing 
world to someone who may not 
need it for a decade or more. Care 
providers, even major international 
development agencies, may come 
and go. Trial sponsors also come 
and go. But providing expanded 
access to treatment is not a transitory 
commitment. As one UNAIDS 
consultant noted, “A lot of these 
sponsors are ready to make the 
commitment ﬁ  nancially [to fund future 
access to care to seroconverting trial 
participants]. But now they’re saying, 
“‘Who do I write the check to?’” (E. 
McGrory, personal communication).
    Drafting a Consensus Statement
    The Global Campaign Consensus 
Statement is informed by structured 
discussion and debate among Global 
Campaign partners, allies, staff, and 
steering committee members during 
three consultations (a much more 
detailed report on the results of these 
deliberations is available in [3]). The 
Statement’s consensus points are 
shown in Box 1, and a longer version 
(which includes details of the origin of 
the consensus, a list of organizational 
endorsers, and a list of the Global 
Campaign for Microbicides’ steering 
committee members) is provided in 
Text S1.
    Drafted in June 2005, the Statement 
was ﬁ  rst presented at a UNAIDS 
meeting on “Creating effective 
partnerships for HIV-prevention 
trials in developing countries.” Held 
in Geneva June 20–21, the meeting 
brought together 70 stakeholders 
from 20 countries—a diverse range of 
civil society representatives, activists, 
researchers, government ofﬁ  cials, 
trial sponsors, and international 
organizations. 
    As the report of this meeting notes, 
“the context of clinical research 
on HIV has changed. Activism has 
empowered previously marginalized 
populations to articulate and demand 
their rights. Changes in possibilities 
and expectations around providing 
treatment for HIV-related disease have 
also profoundly shifted the context; 
affected communities expect access 
to treatment, and are demanding that 
service providers, community groups, 
governments and donors respond” [4].
    The ﬁ  eld as a whole now faces the 
difﬁ  cult challenge of moving from 
generalities to speciﬁ  cs regarding how 
this demand will be met. We drafted 
the Consensus Statement to start the 
ﬁ  eld-wide process of articulating those 
speciﬁ  cs.
    The Challenges of Implementation
    The pathway for operationalizing access 
to care is far from clear, but several 
steps down that path are being taken by 
various entities. 
    One approach to ensuring that 
people who seroconvert during the 
course of a microbicide trial have access 
to HIV care is to initiate trials only in 
areas where HIV treatment roll out is 
occurring already and/or where other 
government-sponsored ART programs 
are already in place. This approach, 
under consideration by several trial 
networks, has its limitations. Such 
programs may be over-subscribed and 
participants may be placed in a long 
queue when they need treatment—
rendering them unable to access care 
in a timely fashion despite theoretical 
accessibility. 
    Some advocates have suggested 
that each research sponsor contribute 
toward the cost of government-
provided ART at a level commensurate 
to the number of participants who 
seroconvert during their trial. Such 
contributions could help relieve some 
of the pressure on over-burdened 
treatment programs and help build 
local health care infrastructure. 
    Another approach—and one being 
considered by at least one major 
microbicide trial network—is that the 
sponsor may commit to paying for 
private care for each seroconverting 
participant as needed until such time 
as adequate care becomes available to 
that participant from a public source in 
her/his country. While this approach 
sidesteps the precariousness of trying to 
expedite access to care through nascent 
government programs, it also introduces 
two major difﬁ  culties: that of creating a 
mechanism to set aside funding (a trust, 
insurance scheme, etc.) to cover the cost 
of care and that of developing durable 
contracts for the provision of future care 
if and when it is needed.
    The latter option also raises the 
specter of undue inducement. Undue 
inducement occurs if the beneﬁ  ts 
offered to trial participants are great 
enough to persuade a potential 
participant to take a risk (by enrolling 
in the trial) that a reasonable person 
would not otherwise take. If trial 
participation enables seroconverting 
participants to “jump the queue” and 
access ARTs promptly either through 
a government program or through 
private providers, is that beneﬁ  t alone 
sufﬁ  cient to induce HIV-negative 
individuals in countries with high HIV 
sero-incidence to enroll in the trial 
when they might otherwise not do so?
    Cathy Slack, an ethicist from the 
University of Kwazulu-Natal, points 
out that data on behavior changes 
during vaccine and microbicide trials 
show that risk behavior generally 
does not increase among enrolled 
trial participants. Indeed, it is more 
likely to decline as the trial progresses 
[5]. Given this, people choosing to 
participate in the trial (whether to 
obtain access to ARTs if they convert 
or for other reasons) are not, in fact, 
taking a risk that a reasonable person 
would avoid. The trial itself does 
not increase participants’ HIV risk, 
provided that the informed consent 
process is done properly and the 
participant is aware of the fact that the 
candidate microbicide cannot be relied 
upon for protection. 
    In developing this Consensus 
Statement, it was clear that we could not 
unravel all the complexities associated 
with negotiating access to care. For this 
reason, a key consensus point is that 
    “UNAIDS or another such body 
should convene a task force of 
clinicians, people living with HIV/
AIDS, advocates, health economists, 
legal and insurance experts and 
entities with relevant experience 
(such as Pharm Access and Médecins 
Sans Frontières) to develop and 
evaluate concrete mechanisms 
for operationalizing ART access 
for those who sero-convert during 
microbicide trials, recognizing that 
they may not need ART for many 
years into the future.” 
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    Developing mechanisms through 
which durable and fair access to 
ARTs can be assured will require 
the committed effort of a carefully 
selected and balanced team of experts. 
This task force will likely have to 
reconvene periodically to adjust these 
mechanisms as established criteria for 
treatment access change, treatment 
rollout progresses, and the landscape 
of health care infrastructure and 
funding evolves.
    But, despite the enormity of the 
challenge, the endorsers of the 
Consensus Statement agree that it 
must be undertaken without delay. 
Prevention trials must go forward. For 
that to happen, access to treatment 
must be assured to those who 
seroconvert during the trial. Given 
these imperatives, we have no choice 
as a ﬁ  eld but to commit ourselves to 
the dauntingly complex challenge of 
ﬁ  guring out how it can be done.
  Lessons  Learned
    The process of developing and 
promulgating this Consensus Statement 
reminds us vividly that bioethical 
decision making is always a balancing 
act. Research requires the rigorously 
controlled implementation of scientiﬁ  c 
protocols. But failing to involve the host 
communities and other stakeholders 
in the trial conceptualization and 
implementation means risking 
difﬁ  culties with participant enrollment 
and retention—and the possibility of 
trial discontinuation.
    Community members have every 
right to demand that sustainable 
improvements in the local standard 
of care occur as a result of hosting 
the trial. Researchers, however, face 
real constraints including the size and 
budget of the trial and the availability 
of support from governments, 
communities, non-governmental 
organizations, and local providers. Thus, 
they cannot be expected to correct all 
the massive inequities in health care 
access that the community experiences.
    Effective and authentic movement 
toward higher levels of stakeholder 
    1. Clinical trial sponsors and researchers 
have a responsibility to ensure 
appropriate care for any negative 
health consequences that participants 
experience as a direct result of trial 
participation.
    2. People who seroconvert during the 
course of a microbicide trial should 
be assured access to high quality HIV 
care, including antiretroviral treatment 
(ART) when it is needed. 
    •  Trial sponsors and donors should 
commit to assuring the availability of 
such care either directly or through 
explicit and durable partnerships 
with other care providers. Such 
agreements should be formalized 
in consultation with relevant 
stakeholders and trial communities 
before a trial starts. 
    •  There is no consensus among 
ethicists as to whether the provision 
of ART to those who seroconvert 
during a microbicide trial is ethically 
obligatory, or “morally praiseworthy” 
but not mandatory. Nonetheless, 
we call on the wider microbicides 
community to ensure access to ART 
based on ethical aspirations and 
existing social and political realities. 
    •  UNAIDS or another such body 
should convene a task force of 
clinicians, people living with HIV/
AIDS, advocates, health economists, 
legal and insurance experts and 
entities with relevant experience 
(such as Pharm Access and Médecins 
Sans Frontières) to develop and 
evaluate concrete mechanisms 
for operationalizing ART access 
for those who seroconvert during 
microbicide trials, recognizing that 
they may not need ART for many 
years into the future. 
    3. Researchers and sponsors, in 
collaboration with local and national 
health authorities, should use 
microbicide trials as an opportunity to 
strengthen and improve local standards 
of care. The minimum objective should 
be to “ratchet up” care in a stepwise, 
sustainable fashion to reduce global 
disparities in access to health care.
  4.  Explicitly  deﬁ  ning each site’s standard 
of care must be a mandatory part of 
trial planning. Negotiations should 
include agreement with stakeholders, 
including relevant community and/or 
civil society groups, on the package 
of prevention services provided to 
participants as well as on what other 
care will be ensured either through 
direct provision or through effective 
referral mechanisms.
    •  Referral arrangements should be 
formalized in writing. Researchers 
and/or trial sponsors should work to 
ensure that adequate care is actually 
received through monitoring and 
support programs for participants 
(e.g. transportation, accompaniment 
programs, etc.). 
    •  Microbicide trials have a special 
obligation to attend to the sexual 
and reproductive health needs of 
participants, including offering 
direct provision of safe, appropriate 
contraception for trial participants. 
Avoidance of unwanted pregnancy 
will also improve trial power 
through participant retention.
    5. Trial participants should have 
preferential access to any test 
product that is shown to be effective. 
Although ensuring immediate 
access is complicated by regulatory, 
manufacturing and licensing issues, 
researchers and donors should actively 
seek to accelerate access to product 
post-trial through implementation of 
observational/introductory studies 
and negotiation with host country 
governments and product sponsors. 
      In addition, the Global Campaign for 
Microbicides commits itself to:
      1. Advocate relentlessly for the right of 
trial communities to have preferential 
access to any product proven safe 
and effective, while being completely 
candid with communities about the 
likely time frame of this access.
    2. Emphasize in our advocacy the 
importance of other aspects of 
standards of care—especially sexual 
and reproductive health care and 
the prevention package offered 
participants  —in addition to HIV care 
and access to ART.
    3. Advocate for the right of host 
communities and countries to have 
an authentic voice in decisions 
around trial-related matters, including 
negotiations of fair beneﬁ  ts. 
    4. Work to increase research and ethics 
literacy among advocates and host 
communities. 
  Box 1. Consensus Points on Access to Treatment and Standards of Care in Microbicides Trials
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involvement requires time—time for 
expanded feasibility studies, community 
preparedness work and “joint literacy” 
training, a process through which 
researchers are educated about the 
realities and priorities of their trial 
host communities while community 
members and activists are educated 
about the realities and constraints 
of doing research. When it comes to 
HIV prevention, however, the cost of 
delay is paid in human lives. Where 
is the appropriate balance between 
the urgency of developing new HIV-
prevention methods and the need 
to respect and advance the human 
rights of trial participants and host 
communities?
    A political consensus has emerged 
around seroconverting trial 
participants’ right to ART access. 
Given ﬁ  nite resources, how can 
funding this commitment to the 
few who seroconvert be balanced 
against funding the provision of other 
kinds of care—especially sexual and 
reproductive health care—to all trial 
participants (and possibly to the whole 
of the host community)? Further, 
how do we balance this political 
consensus against the sovereign right 
of host communities and countries 
to determine the most advantageous 
beneﬁ  ts package they can negotiate 
(which may or may not include 
primary focus on ART provision)?
    Knowing that clinical trials can 
be stopped by broad-based public 
opposition provides considerable 
impetus to action. But neither 
researchers, nor sponsors, nor activists, 
nor host community members can 
unilaterally resolve the questions of 
how to operationalize access to care—
much less balance delicate ethical 
equations such as those mentioned 
above. Collaboration and transparency, 
however difﬁ  cult to achieve, will be 
required. 
    Multilateral advocacy work will also 
be needed to raise the resources and 
exert the political pressure required to 
make full access to care a sustainable 
reality in trial host communities. 
Governments can and must be 
involved in decisions regarding 
where trials can be conducted and 
kept constantly informed of trial 
progress. Involving them not only 
draws their attention to the need to 
ratchet up the standard of care in 
those communities, but also helps 
to build their commitment to, and 
support for, microbicide research and 
development. 
    The activists and trial host 
communities who put this issue so 
forcefully on the agenda must now 
insist that researchers and sponsors 
join them in advocating to local 
governments and international 
funders for their active and escalating 
investment in this process. Ethicist 
Solomon Benatar and Kathy Shapiro, a 
behavioral scientist, have noted that the 
fact that “the ideal of ﬁ  rst world health 
care cannot be achieved immediately 
in developing countries should not be 
a deterrent to efforts to raise existing 
levels of care” [6].
    We are walking a difﬁ  cult line 
between two imperatives: responding to 
the urgency of the HIV epidemic and 
maintaining rigorous ethical standards 
in HIV-prevention trials. We need to 
move forward carefully but quickly on 
that tightrope, recognizing the fact that 
it is only by truly listening to each other 
that we can maintain our balance.  
  Supporting  Information
      Text S1.   Full Length Version of the 
Consensus Points on Access to Treatment 
and Standards of Care in Microbicides Trials
    Found at DOI: 10.1371/journal.
pmed.0030153.sd001 (100 KB DOC). 
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